Financials data is unavailable for this security.
View more
Year on year Vertex Pharmaceuticals Inc grew net income 8.96% from 3.32bn to 3.62bn primarily through revenue growth (8.93bn to 9.87bn). For while the costs associated with cost of goods, selling, general and administrative and debt all increased as a percentage of sales, the 10.51% growth in revenues contributed enough to still see net income improve.
| Gross margin | 86.12% |
|---|---|
| Net profit margin | -4.52% |
| Operating margin | -2.54% |
| Return on assets | -2.18% |
|---|---|
| Return on equity | -2.99% |
| Return on investment | -2.64% |
More ▼
Cash flow in USDView more
In 2023, Vertex Pharmaceuticals Inc did not generate a significant amount of cash. However, the company earned 3.54bn from its operations for a Cash Flow Margin of 35.84%. In addition the company used 3.14bn on investing activities and also paid 562.20m in financing cash flows.
| Cash flow per share | -0.9994 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 60.65 |
|---|---|
| Tangible book value per share | 53.20 |
More ▼
Balance sheet in USDView more
| Current ratio | 2.47 |
|---|---|
| Quick ratio | 2.20 |
| Total debt/total equity | 0.0073 |
|---|---|
| Total debt/total capital | 0.0072 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items increased 8.37%. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
| EPS growth(5 years) | 46.35 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -114.95 |
